StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.15−0.11 (-8.73%)

Close on Nov 17, 2026Market cap $25.17MP/E –Yield –

Aardvark Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aardvark Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$69.41M. For fiscal 2025 it was -$54.17M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$54.17M–
FY2024Dec 31, 2024-$18.09M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.60M–
Q1 FY2026Mar 31, 2026-$18.87M–
Q4 FY2025Dec 31, 2025-$16.81M–
Q3 FY2025Sep 30, 2025-$16.13M–
Q2 FY2025Jun 30, 2025-$9.84M–
Q1 FY2025Mar 31, 2025-$11.39M–
Q4 FY2024Dec 31, 2024-$7.73M–
Q3 FY2024Sep 30, 2024-$3.96M–
Q2 FY2024Jun 30, 2024-$4.22M–
Q1 FY2024Mar 31, 2024-$2.19M–

More Aardvark Therapeutics figures

See a number that looks wrong?